## Risk Stratification in Localised Prostate Cancer ### Risk Classification Framework **Key Point:** Risk stratification in localised prostate cancer (D'Amico / NCCN criteria) is based on PSA level, Gleason/Grade Group, and clinical T stage. Seminal vesicle invasion (SVI) — classified as **T3b** — is an unambiguous, definitive criterion for **high-risk** localised disease, clearly distinguishing it from intermediate-risk disease. ### Risk Stratification Criteria (NCCN / D'Amico) | Risk Category | PSA (ng/mL) | Gleason Score | Clinical T Stage | |---------------|-------------|---------------|------------------| | **Low** | <10 | ≤6 (GG1) | T1–T2a | | **Intermediate** | 10–20 | 7 (GG2–3) | T2b–T2c | | **High** | >20 OR | ≥8 (GG4–5) | **T3–T4** | **T3 sub-staging:** - **T3a** = Extraprostatic extension (EPE) — can be seen in both intermediate-unfavourable and high-risk categories - **T3b** = Seminal vesicle invasion (SVI) — **definitively high-risk** ### Analysis of This Case **Clinical Context:** - PSA = 28 ng/mL (already in high-risk PSA range, but borderline) - Gleason 7 (4+3) = Grade Group 3 (intermediate-unfavourable) - The question asks which staging finding **best distinguishes** intermediate from high-risk **Why Seminal Vesicle Involvement (Option C) is the Best Discriminator:** 1. **Definitive T3b staging:** SVI upstages the patient to T3b, which is an explicit high-risk criterion in both D'Amico and NCCN guidelines — there is no ambiguity. 2. **EPE (Option A) is insufficient alone:** Extraprostatic extension (T3a) is present in intermediate-unfavourable disease as well as high-risk disease. It does NOT unambiguously distinguish the two categories — a patient with Gleason 7 and EPE alone may still be classified as intermediate-unfavourable by some risk tools (e.g., CAPRA score). 3. **SVI is unambiguously high-risk:** Any patient with SVI is classified as high-risk regardless of PSA or Gleason score, making it the **best discriminator** between intermediate and high-risk localised disease. ### Why Other Options Are Incorrect - **Option A (EPE on MRI):** T3a disease can occur in intermediate-unfavourable prostate cancer; EPE alone does not definitively place a patient in the high-risk category across all major guidelines. - **Option B (PSA density >0.15):** PSA density is used for biopsy decision-making and active surveillance eligibility — it is **not** part of standard D'Amico or NCCN risk stratification criteria. - **Option D (Elevated alkaline phosphatase):** Suggests bone metastases (M1b disease) — this is **metastatic**, not localised, prostate cancer and is outside the scope of localised risk stratification. **High-Yield:** Per NCCN Prostate Cancer Guidelines 2023 and Campbell-Walsh Urology 12e, **seminal vesicle invasion (T3b)** is a definitive high-risk feature. EPE (T3a) alone is insufficient to unambiguously distinguish intermediate from high-risk localised disease. **Clinical Pearl:** In a patient with Gleason 7 (4+3) and PSA 28 ng/mL, detection of SVI on MRI or biopsy mandates high-risk management: external beam radiotherapy + long-term androgen deprivation therapy (≥2 years), or radical prostatectomy with extended pelvic lymph node dissection. [cite: NCCN Clinical Practice Guidelines in Oncology — Prostate Cancer v2.2023; Campbell-Walsh Urology 12e Ch 126; D'Amico AV et al., JAMA 1998]
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.